- Shape the Future of Your Health and Explore Your Ancestry with DNA Complete®
- World-class Whole Genome Sequencing Direct-to-Consumer test offering
- Offering deep insights for consumers, universities, and the healthcare industry with best-in-class tools and interpretation capabilities
About Us
“We believe we are destined to become a multibillion company. Our focused execution and smart diversification strategy have delivered stellar financial results, while the acquisition, licensing, and development of cutting-edge assets have billion-dollar potential. The best is yet to come.”
– Ted Karkus
ProPhase Labs is a next- generation biotech, genomics and diagnostics company focused on creating a healthier world through bold action and the power of insight. Find us on the Nasdaq, stock symbol PRPH.
We dream big and execute smartly through our diversified subsidiaries.
- The pioneers and leader in Whole Genome Sequencing with one of the most accurate, highest quality and price competitive solutions on the market.
- Developing groundbreaking compounds and products.
- Licensing and developing with the goal of commercializing Equivir (dietary supplement) and Equivir G (Rx), two broad based anti-virals.
- Introducing BE-Smart, a breakthrough in esophageal cancer detection.
- Clinically-backed consumer products promoting better health, energy, and sexual vitality available online, Walmart, Walgreens, CVS, Rite-Aid and more.
We achieve extraordinary results with our focus on executional excellence, smart diversification, and a synergistic approach
Meet Our Management Team
Ted Karkus
Chairman & CEO
Ted Karkus, CEO and Chairman of ProPhase Labs, drives the company’s diverse and synergistic businesses with his successful track record in biomedical and health companies. He transformed ID Biomedical’s strategy and valuation from $25 million to $1.4 billion sale to GlaxoSmithKline. As CEO of ProPhase Labs, he restructured the go-to-market strategy for the flagship product Cold-EEZE, turned around and significantly grew revenues, ultimately selling it for $50 million to Mylan.
ProPhase Labs is a fast-growing biotech, genomics and diagnostics company due to its commitment to growth, innovation, and execution excellence outlined in Ted’s high growth roadmap. He pivoted into industry leading CLIA labs, and then further diversified by acquiring genomics leader Nebula Genomics. Constantly innovating, Ted then created ProPhase BioPharma to deliver antivirals, cancer tests and therapeutic cancer compounds. The new acquisitions and legacy businesses work to drive synergistic growth with multi-billion-dollar potential.
He holds a BS in Psychology from Tufts University with Magna Cum Laude Honors and an MBA in Finance from Columbia University School of Business with Beta Gamma Sigma Honors.
Stu Hollenshead
Chief Operating Officer
Stu Hollenshead is a seasoned C-level executive with 15+ years of experience in media, e-commerce, marketing, and technology. He has led growth, monetization, and audience engagement for top digital brands.
At TheStreet, he scaled DTC subscriptions to $30M and pioneered AI-driven content automation. At Business Insider, he drove audience growth, contributing to its $442M acquisition by Axel Springer. At WWE, he helped WWE Network reach nearly 2M subscribers.
As COO & CBO of Barstool Sports, he led record-breaking expansion, culminating in its $551M acquisition by Penn Entertainment. Now simultaneously CEO of 10PM Curfew, a female-centric platform with an audience of 70M+, Stu continues to build and scale high-growth businesses each and every day.
Jason Karkus
President, Nebula Genomics
Jason drove explosive revenue growth at ProPhase Diagnostics, leading multiple areas including sales, business development, logistics operations, and account management. He oversaw the development of two CLIA-certified labs, generating approximately $200 million in revenues since 2021 and manages account managers and customer service reps who offer 24/7 service to exceed customer expectations. Jason now heads up business development for the rapid build-out of ProPhase’s clinical and genomic businesses.
With a background in sales and development at top real estate firms, Jason is a graduate of the University of Maryland.
Lance Bisesar
Head of Finance, corporate controller ProPhase Labs, Inc.
Lance is an accomplished finance leader experienced in all areas of finance and accounting. Lance has over 17 years of experience in working with large brands, both public and private, of varying industries and sizes.
Prior to ProPhase Labs, Lance served in finance leadership roles at multiple large brand companies including Colgate-Palmolive, Casper Sleep, Newmark and Forest Laboratories, where he was responsible for all accounting matters including financial reporting, general accounting, and related internal controls functions. He began his career with five years in public accounting with Marcum LLP. Lance earned a BBA in accounting from Hofstra University. He is a certified public accountant and is a member of the American Institute of Certified Public Accountants.